Sandoz Group AG (XSWX:SDZ) Retained Earnings: CHF0 Mil (As of Dec. 2025)


XSWX:SDZ Sandoz Group AG XSWX:SDZ
11 GF Score
Price CHF67.78
! 6 Warning Signs
View Full Analysis

What is Sandoz Group AG Retained Earnings?

Sandoz Group AG XSWX:SDZ -1.20% 11 Retained Earnings is CHF0 Mil as of Dec. 2025. GuruFocus rates XSWX:SDZ with a GF Score™ of 11/100. The stock has 6 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Sandoz Group AG's retained earnings for the quarter that ended in Dec. 2025 was CHF0 Mil.

Sandoz Group AG  (XSWX:SDZ) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Sandoz Group AG Retained Earnings Historical Data

* Premium members only.

The historical data trend for Sandoz Group AG's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandoz Group AG Retained Earnings Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Retained Earnings
0.00 0.00 0.00 0.00

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
XSWX:SDZ
11GF Score
Sandoz Group AG XSWX:SDZ
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sandoz Group AG Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of CHF0 Mil mean?
Sandoz Group AG (XSWX:SDZ) has a Retained Earnings of CHF0 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Sandoz Group AG and its competitors.
Is Sandoz Group AG's Retained Earnings too high?
Sandoz Group AG's current Retained Earnings is CHF0 Mil. Overall, Sandoz Group AG has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Retained Earnings compare to ZTS and UTHR?
Sandoz Group AG's Retained Earnings of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Sandoz Group AG and its competitors. Sandoz Group AG's current Retained Earnings is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (XSWX:SDZ) has a current Retained Earnings of CHF0 Mil. The current Retained Earnings is CHF0 Mil. Sandoz Group AG's overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Sandoz Group AG (XSWX:SDZ), the current Retained Earnings is CHF0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sandoz Group AG Business Description

Address Centralbahnstrasse 4, Basel, CHE, 4051
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
11GF Score

Get the complete analysis for XSWX:SDZ

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF67.78
Price